Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on April 21, 2006, where 75,164 Ordinary shares were transferred from the SmithKline Beecham Employee Benefit Trust to participants in the GlaxoSmithKline Annual Investment Plan. This transfer impacts the share interests of Mr. J Heslop, a director, who holds an interest in the fund alongside other non-US employees and former employees.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the share transfer.
Investor Verification Points
- Verify the total number of shares transferred from the Employee Benefit Trust (75,164 shares).
- Confirm the transaction date (April 21, 2006) and notification date (April 24, 2006).
- Identify the specific director with an interest in the fund (Mr. J Heslop).
- Note that this filing does not contain financial performance data for the period.